Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
M&A / Property

DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx(TM) Red Eye Diagnostic Test

By The Northwire Desk — AI Analysis Nov 26, 2025 · 16:16 DTR · 0.4 DiagnosTear Technologies Inc.
DTR · Price

Executive Summary

  • DiagnosTear Technologies Inc. announced a scientific collaboration with LV Prasad Eye Institute (LVPEI) in Hyderabad, India to clinically validate its TeaRx™ point‑of‑care red‑eye diagnostic test.
  • LVPEI will supply well‑characterized clinical samples, including a cohort of PCR‑confirmed Herpetic Keratitis patients, for analytical and clinical performance evaluation of the TeaRx™ platform.
  • The data generated from this study will support FDA regulatory submissions and preparation for commercial launch of the multi‑parametric red‑eye test.

Key Details

  • Collaboration Scope: LVPEI provides access to clinical samples; DiagnosTear conducts testing and refinement of TeaRx™ diagnostic assay.
  • Target Conditions: Differentiation among Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis using tear‑fluid analysis.
  • Regulatory Impact: Clinical data will be used to support FDA regulatory pathway for the TeaRx™ test.
  • Commercial Outlook: Partnership aims to accelerate market entry of the first point‑of‑care, multi‑parametric red‑eye diagnostic test.

Notable Quotes

“This collaboration with LV Prasad Eye Institute accelerates our goal of bringing the first point of care, multi‑parametric test for differential diagnosis of red eye, and specifically for on‑site detection of Herpes viruses,” – Dr. Shimon Gross, CEO, DiagnosTear Technologies Inc.

Read the original news release →

More from DiagnosTear Technologies Inc.

Jun 05, 2026 · 08:31

DiagnosTear’s TeaRx Validation Fails to Halt 65% Decline as CLARIFY Royalties Weigh on Near-Term Upside

Other May 12, 2026 · 16:06

DiagnosTear Solidifies CLARIFY License, Moving from Dry-Eye to Blood Diagnostics, but Commercialization Cliff Looms

Other Feb 26, 2026 · 17:01

DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye

Regulatory Feb 20, 2026 · 17:01

DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

M&A / Property Jan 22, 2026 · 17:01

DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India

M&A / Property Dec 17, 2025 · 18:01

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Other